权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

EXPLOITATION OF NEW DIAGNO-THERAPEUTIC PROCEDURES OF HUMAN UTERINE CANCER BASED ON MOLECULAR CYTOGENETIC STUDY

基于分子细胞遗传学研究的人类子宫癌新诊断治疗方法的开发

基本信息

批准号：
17591770
负责人：
HIRAI Yasuo
金额：
$ 2.39万
依托单位：
Japanese Foundation For Cancer Research
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2007
项目状态：
已结题

项目摘要

In our institute, rare clinical materials from both endocervical and endometrial adenocarcinomas are available for several investigations. We investigated new diagno-therapeutic procedures of human uterine cancer based on molecular cytogenetic study. The array-based CGH analysis of endocervical adenocarcinomas revealed decreasing copy numbers in LRP1B (2q21.2) DAB2 (5p13), and DCC (18q21.3). These genetic changes are presumably specific to the endocervical adenocarcinomas, which may be engaged in the carcinogenesis. As the chemotherapy for uterine cancers is usually effective, surgical or radiation therapy combined with neoadjuvant and/or adjuvant chemotherapy is expected to improve significantly over all survival of the patients. Therefore, any prediction of chemotherapeutic sensitivity may be helpful for therapeutic decisions associated with switching from surgery to radiation therapy and so forth.Recently, a high rate of endometrial cancer has been reported in women with hereditary nonpolyposis colorectal cancer (HNPCC), suggesting a relation between familial endometrial cancers and HNPCC. Familial endometrial cancers constitute only about 0.5% of all endometrial carcinomas and it is essential to examine family histories in detail. We performed a mutational analysis of three DNA mismatch repair (MMR) genes (hMLH1, hMSH2 and hMSH6) in patients with endometrial cancer who meet our criteria for familial predisposition to HNPCC-associated endometrial cancers.

在我们的研究所，罕见的临床资料，从宫颈和子宫内膜腺癌的几个研究是可用的。我们探讨了基于分子细胞遗传学研究的子宫癌诊断治疗新方法。基于阵列的宫颈腺癌CGH分析显示LRP1B （2q21.2）、DAB2 （5p13）和DCC （18q21.3）拷贝数减少。这些基因变化可能是宫颈内腺癌所特有的，可能参与了癌变过程。由于子宫癌的化疗通常是有效的，手术或放疗联合新辅助和/或辅助化疗有望显著提高患者的总体生存率。因此，任何化疗敏感性的预测都可能有助于从手术转向放射治疗等相关的治疗决策。近年来，有报道称遗传性非息肉病性结直肠癌（HNPCC）患者的子宫内膜癌发生率较高，提示家族性子宫内膜癌与HNPCC之间存在一定的关系。家族性子宫内膜癌仅占所有子宫内膜癌的0.5%，详细检查家族史是必要的。我们对符合hnpcc相关子宫内膜癌家族易感性标准的子宫内膜癌患者进行了三种DNA错配修复（MMR）基因（hMLH1， hMSH2和hMSH6）的突变分析。